Adverse reactions to drugs are a significant cause of death and injuryin infants and children younger than 2 years, according to a report in theNovember issue of Pediatrics. The potential for adverse reactions in childrenis higher than it is in adults because young children have immature detoxificationmechanisms and because doses must be adjusted over a very wide range ofbody size and weight.
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More